- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2013
- Public Summary Document (PSD) March 2013 PBAC Meeting - PDF
Rivaroxaban (spaf) – March 2013
Rivaroxaban (SPAF), tablets, 15 mg and 20 mg, Xarelto®
Last updated
8 November 2023